BMJ August 18, 2016, 354 i4079; DOI: https://doi.org/10.1136/bmj.i4079
Cited by...
Risk for lower intestinal perforations in patients with rheumatoid arthritis treated with tocilizumab in comparison to treatment with other biologic or conventional synthetic DMARDs